Patents by Inventor Krishna Murthy Ella
Krishna Murthy Ella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10576138Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.Type: GrantFiled: August 1, 2018Date of Patent: March 3, 2020Assignee: Bharat Biotech International Ltd.Inventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
-
Patent number: 10543266Abstract: The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost-effective and affordable, especially for lower-middle income and low-income countries.Type: GrantFiled: July 4, 2016Date of Patent: January 28, 2020Assignee: Bharat Biotech International Ltd.Inventors: Krishna Murthy Ella, Ashawani Kumar, Venkatesan Ramaswamy, Voleti Subrahmanya Ramachandra Murthy
-
Publication number: 20190142932Abstract: A buffer free, acid stable, low dose volume rotavirus vaccine is disclosed. The vaccine is available in dose volume of less than 1 ml per dose for oral administration and it is without any buffer. The vaccine also does not require pre or post administration of any antacid at the time of oral administration of the vaccine to the subject to neutralize the stomach acid. The vaccine exemplifies nominal drop in vaccine titer at pH 2-4 for a time span of 30 minutes. The vaccine is stable at ?20° C. for at least 60 months.Type: ApplicationFiled: June 13, 2017Publication date: May 16, 2019Applicant: Bharat Biotech International LimitedInventors: Krishna Mohan Vadrevu, Sai Devarajulu Prasad, Krishna Murthy Ella
-
Publication number: 20180371023Abstract: The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof. Wherein, R can be both linear and branched alkyl, aryl, substituted aryl and alkoxy alkyl. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are, particularly useful as adjuvants in vaccines.Type: ApplicationFiled: December 6, 2016Publication date: December 27, 2018Applicants: BHARAT BIOTECH INTERNATIONAL LIMITED, COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Krishna Murthy Ella, Ganneru Brunda, Halmathur Mahabalarao Sampath Kumar, Miryala Sreekanth
-
Publication number: 20180360957Abstract: The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof; wherein R1 and R2 both are hydrogen; or R1 is hydrogen and R2 is alkyl or aryl; or R1 is alkyl or aryl and R2 is hydrogen; or R1 and R2 both are alkyl or aryl (same or different groups); wherein alkyl group constitute C1-C6 alkyl or higher (both linear and branched) with or without heteroatoms; and aryl group constitute phenyl, substituted phenyl, heteraryl, arylalkyl and polynuclear aromatics. These compounds possess excellent pharmacological properties, in particular immunomodulating properties for use as adjuvant in vaccine formulations. These compounds are, particularly useful as adjuvants in vaccines.Type: ApplicationFiled: December 10, 2016Publication date: December 20, 2018Applicants: BHARAT BIOTECH INTERNATIONAL LIMITED, COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Krishna Murthy Ella, Ganneru Brunda, Halmathur Mahabalarao Sampath Kumar, Miryala Sreekanth
-
Publication number: 20180353590Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.Type: ApplicationFiled: August 1, 2018Publication date: December 13, 2018Applicant: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
-
Publication number: 20180353589Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.Type: ApplicationFiled: August 1, 2018Publication date: December 13, 2018Applicant: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
-
Publication number: 20180339033Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S.typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.Type: ApplicationFiled: August 2, 2018Publication date: November 29, 2018Applicant: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
-
Patent number: 10058605Abstract: Vaccine combinations which comprise at least two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of preparing the vaccine combinations are disclosed. Nucleic acids encoding the antigens, as well as methods for their production and use are provided.Type: GrantFiled: May 9, 2013Date of Patent: August 28, 2018Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Kandaswamy Sumathy
-
Patent number: 10046039Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.Type: GrantFiled: August 19, 2014Date of Patent: August 14, 2018Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
-
Publication number: 20180185465Abstract: The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost-effective and affordable, especially for lower-middle income and low-income countries.Type: ApplicationFiled: July 4, 2016Publication date: July 5, 2018Applicant: BHARAT BIOTECH INTERNATIONAL LIMITEDInventors: Krishna Murthy ELLA, Ashawani KUMAR, Venkatesan RAMASWAMY, Voleti Subrahmanya Ramachandra MURTHY
-
Patent number: 9844588Abstract: A vaccine composition for prophylaxis and treatment of Chikungunya virus infections is disclosed which is capable of conferring immunity against any genotypic variants of the Chikungunya virus. More particularly the invention discloses particular nucleotide sequences and their translated proteins thereof, which may be expressed as Virus Like Particles which for use as a vaccine antigens against Chikungunya virus infections. The compositions disclosed in this invention are also protective against any genotypic variants of the Chikungunya virus which may be propagated by any suitable vector of the disease including Aedis albopictus and Aedis aegypti.Type: GrantFiled: June 18, 2012Date of Patent: December 19, 2017Assignee: BHARAT BIOTECH INTERNATIONAL LIMITEDInventors: Krishna Murthy Ella, Sumathy Kandaswamy
-
Patent number: 9642907Abstract: The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human.Type: GrantFiled: May 11, 2007Date of Patent: May 9, 2017Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Victor Jerusha Augustus Harshavardhan Gutla, Krishna Mohan Vadrevu, Smita Suneel Singhania
-
Publication number: 20170014502Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.Type: ApplicationFiled: July 18, 2016Publication date: January 19, 2017Inventors: Kandaswamy SUMATHY, Krishna Murthy Ella
-
Publication number: 20160206721Abstract: Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.Type: ApplicationFiled: August 19, 2014Publication date: July 21, 2016Inventors: Krishna Murthy Ella, Venkatesan Ramasamy, Mandalapu Gangadhara Naidu
-
Publication number: 20160015804Abstract: Vaccine combinations which comprise at least two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of preparing the vaccine combinations are disclosed. Nucleic acids encoding the antigens, as well as methods for their production and use are provided.Type: ApplicationFiled: May 9, 2013Publication date: January 21, 2016Inventors: Krishna Murthy ELLA, Kandaswamy SUMATHY
-
Patent number: 8968728Abstract: New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.Type: GrantFiled: May 11, 2007Date of Patent: March 3, 2015Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Kandaswamy Sumathy
-
Patent number: 8956812Abstract: A novel process for the purification of recombinant protein expressed as particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.Type: GrantFiled: August 23, 2004Date of Patent: February 17, 2015Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
-
Patent number: 8754043Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.Type: GrantFiled: June 6, 2013Date of Patent: June 17, 2014Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
-
Publication number: 20140120125Abstract: A vaccine composition for prophylaxis and treatment of Chikungunya virus infections is disclosed which is capable of conferring immunity against any genotypic variants of the Chikungunya virus. More particularly the invention discloses particular nucleotide sequences and their translated proteins thereof, which may be expressed as Virus Like Particles which for use as a vaccine antigens against Chikungunya virus infections. The compositions disclosed in this invention are also protective against any genotypic variants of the Chikungunya virus which may be propagated by any suitable vector of the disease including Aedis albopictus and Aedis aegypti.Type: ApplicationFiled: June 18, 2012Publication date: May 1, 2014Applicant: Bharat Biotech International LimetedInventors: Krishna Murthy Ella, Sumathy Kandaswamy